{
  "eval_id": "S11",
  "eval_file": "evals/single/S11.json",
  "timestamp": "2025-09-18T16:39:49.752575Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated in HR-positive, HER2-negative advanced breast cancer after endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. The main on-label point is its use as a later-line option for patients who have progressed on standard treatments. For details on efficacy, tolerability, and patient selection, please send the EMA SmPC or EPAR by email."
}